Category: TNF alpha

Neurological manifestations of post-acute sequelae of COVID-19: which liquid biomarker should we use?

Posted on | Posted on John Murphy | Leave a Comment on Neurological manifestations of post-acute sequelae of COVID-19: which liquid biomarker should we use?

Dominique Comeau1† Mykella Martin2† Gilles A. Robichaud3,4,5 Ludivine Chamard-Witkowski2,6*1Dr. Georges-L. Long COVID syndrome, also known as post-acute sequelae of COVID-19 (PASC), is characterized by persistent symptoms lasting 3–12 weeks post SARS-CoV-2 infection. Patients suffering from PASC can display a myriad of symptoms that greatly diminish quality of life, the most frequent being neuropsychiatric. Thus, there is an eminent need […]

Alteration of the blood-brain barrier by COVID-19 and its implication in the permeation of drugs into the brain

Posted on | Posted on John Murphy | Leave a Comment on Alteration of the blood-brain barrier by COVID-19 and its implication in the permeation of drugs into the brain

Héctor Hernández-Parra1,2 Octavio Daniel Reyes-Hernández3 Gabriela Figueroa-González4 Manuel González-Del Carmen5 Maykel González-Torres6 Sheila I. Peña-Corona2 Benjamín Florán7 Hernán Cortés8* Gerardo Leyva-Gómez2* https://pubmed.ncbi.nlm.nih.gov/36998270/ Diverse neurological symptoms have been reported in patients with SARS-CoV-2 disease (COVID-19), including stroke, ataxia, meningitis, encephalitis, and cognitive impairment. These alterations can cause serious sequelae or death and are associated with the entry of SARS-CoV-2 into the Central Nervous System […]

Skin reactions to COVID-19 vaccines?  

Posted on | Posted on John Murphy | Leave a Comment on Skin reactions to COVID-19 vaccines?  

2020-January 18 The coronavirus disease 2019 (COVID-19) pandemic has led to the development and approval of vaccines against the responsible virus — severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). More than 100 companies and institutions worldwide have developed vaccine candidates.  How do the COVID-19 vaccines differ? Current approved vaccines rely on a nucleic-acid-based vaccine platform Messenger ribonucleic acid (mRNA) eg, Pfizer/BioNTech + Fosun Pharma, Moderna + National Institute […]

Toxic Epidermal Necrolysis Post COVID-19 Vaccination – First Reported Case

Posted on | Posted on John Murphy | Leave a Comment on Toxic Epidermal Necrolysis Post COVID-19 Vaccination – First Reported Case

Authors: Mohamad Bakir, Hanan Almeshal, Rifah Alturki, Sulaiman Obaid, Areej Almazroo Published: August 16, 2021 Abstract Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum of acute, delayed-type hypersensitivity reactions that affect the skin and the mucous membranes. Medications are the culprit cause of these disorders in addition to infections and in very rare instances vaccinations. We report a case of […]

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Posted on | Posted on John Murphy | Leave a Comment on SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Authors: Víctor J Costela-Ruiz 1, Rebeca Illescas-Montes 1, Jose M Puerta-Puerta 2, Concepción Ruiz 3, Lucia Melguizo-Rodríguez 1 COVID-19 disease, caused by infection with SARS-CoV-2, is related to a series of physiopathological mechanisms that mobilize a wide variety of biomolecules, mainly immunological in nature. In the most severe cases, the prognosis can be markedly worsened by the hyperproduction of mainly proinflammatory cytokines, such as […]

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

Posted on | Posted on John Murphy | Leave a Comment on Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

Authors: Mehmet Soy 1, Gökhan Keser 2, Pamir Atagündüz 3, Fehmi Tabak 4, Işık Atagündüz 5, Servet Kayhan COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may […]

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment

Posted on | Posted on John Murphy | Leave a Comment on Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment

Authors: Philip C Robinson, Duncan Richards, Helen L Tanner, Marc Feldmann The COVID-19 pandemic continues to wreak havoc on global health-care systems and to claim an increasing number of lives. Although some treatments have shown promise, including dexamethasone and remdesivir, problems remain with access to medication and high mortality despite treatment. Patient selection also appears […]

TNF Biologics and COVID-19: What Autoimmune Patients Need to Know

Posted on | Posted on John Murphy | Leave a Comment on TNF Biologics and COVID-19: What Autoimmune Patients Need to Know

Authors: If you’re taking a type of medication known as tumor necrosis factor inhibitors, also called anti-TNF or TNFis, you may be wondering how these drugs could impact your chances of contracting COVID-19, or having more severe complications from it. After all, the common cold or other upper respiratory tract infections can be more common […]

Pathways in the Pathophysiology of Coronavirus 19 Lung Disease Accessible to Prevention and Treatment

Posted on | Posted on John Murphy | Leave a Comment on Pathways in the Pathophysiology of Coronavirus 19 Lung Disease Accessible to Prevention and Treatment

Authors: Michael Eisenhut 1, Jae Il Shin 2 Background: In COVID 19 related lung disease, which is a leading cause of death from this disease, cytokines like tumor necrosis factor-alpha (TNF alpha) may be pivotal in the pathogenesis. TNF alpha reduces fluid absorption due to impairment of sodium and chloride transport required for building an osmotic gradient across epithelial […]